KR20130055553A - 환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법 - Google Patents

환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법 Download PDF

Info

Publication number
KR20130055553A
KR20130055553A KR1020127009956A KR20127009956A KR20130055553A KR 20130055553 A KR20130055553 A KR 20130055553A KR 1020127009956 A KR1020127009956 A KR 1020127009956A KR 20127009956 A KR20127009956 A KR 20127009956A KR 20130055553 A KR20130055553 A KR 20130055553A
Authority
KR
South Korea
Prior art keywords
genes
gene
responder
patient
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127009956A
Other languages
English (en)
Korean (ko)
Inventor
빈센트 브리차드
벤자민 게오르기스 엘리 리아 기히스라인 디지어
올리비어 그루셀리
자밀라 로우아헤드
페르난도 울로아-몬토야
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20130055553A publication Critical patent/KR20130055553A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020127009956A 2009-09-18 2010-09-17 환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법 Withdrawn KR20130055553A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27704609P 2009-09-18 2009-09-18
US61/277,046 2009-09-18
US27838709P 2009-10-06 2009-10-06
GBGB0917457.4A GB0917457D0 (en) 2009-10-06 2009-10-06 Method
US61/278,387 2009-10-06
GB0917457.4 2009-10-06
PCT/EP2010/063751 WO2011033095A1 (en) 2009-09-18 2010-09-17 Method for identifying whether a patient will be responder or not to immunotherapy

Publications (1)

Publication Number Publication Date
KR20130055553A true KR20130055553A (ko) 2013-05-28

Family

ID=41393894

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127009956A Withdrawn KR20130055553A (ko) 2009-09-18 2010-09-17 환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법

Country Status (14)

Country Link
US (1) US20110070268A1 (enExample)
EP (1) EP2478116A1 (enExample)
JP (1) JP2013505008A (enExample)
KR (1) KR20130055553A (enExample)
CN (1) CN102597269A (enExample)
AU (1) AU2010297248A1 (enExample)
BR (1) BR112012006088A2 (enExample)
CA (1) CA2773666A1 (enExample)
EA (1) EA201290107A1 (enExample)
GB (1) GB0917457D0 (enExample)
IL (1) IL218313A0 (enExample)
MX (1) MX2012003329A (enExample)
SG (1) SG179129A1 (enExample)
WO (1) WO2011033095A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906523A1 (en) * 2013-03-15 2014-09-25 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
ES2946681T3 (es) 2014-07-02 2023-07-24 Myriad Mypath Llc Genes y firmas génicas para el diagnóstico y tratamiento del melanoma
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
KR20180126085A (ko) * 2016-05-05 2018-11-26 난토믹스, 엘엘씨 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor)
IL296568A (en) * 2020-03-17 2022-11-01 Regeneron Pharma Methods and systems for determining responders to treatment
EP4161658A4 (en) * 2020-06-01 2024-10-02 Dana-Farber Cancer Institute, Inc. Methods for modulating mhc-i expression and immunotherapy uses thereof
CN115495026B (zh) * 2022-11-21 2023-03-10 杭州字节方舟科技有限公司 一种优化内存处理方法、装置、设备及存储介质

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CA2319309C (en) 1998-02-05 2010-08-10 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
DE69929444T2 (de) 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
CA2361009C (en) 1999-01-29 2012-10-23 Corixa Corporation Her-2/neu fusion proteins
CN100430478C (zh) 1999-03-11 2008-11-05 史密丝克莱恩比彻姆生物有限公司 Casb618多核苷酸和多肽及其用途
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
PL209127B1 (pl) 2000-02-23 2011-07-29 Smithkline Beecham Biolog Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
EP1482795B1 (en) 2002-02-04 2009-11-11 Corixa Corporation New immunoeffector compounds
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
MXPA04012443A (es) 2002-06-11 2005-04-19 Glaxosmithkline Biolog Sa Composiciones inmunogenicas.
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004076565A2 (en) * 2003-02-25 2004-09-10 Technical Knockout, Inc. Improved coated weight plates, dumbbells and method of manufacture
EP1605811A4 (en) * 2003-02-28 2008-06-11 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR BREAST CANCER AND METHODS OF USE
US20050095607A1 (en) * 2003-03-07 2005-05-05 Arcturus Bioscience, Inc. University Of Louisville Breast cancer signatures
EP1608964A4 (en) 2003-03-14 2009-07-15 Peter Maccallum Cancer Inst CREATING AN EXPRESSION PROFILE OF TUMORS
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JP2007507222A (ja) * 2003-05-28 2007-03-29 ゲノミック ヘルス， インコーポレイテッド 化学療法に対する応答を予測するための遺伝子発現マーカー
EP2348110B1 (en) 2003-05-30 2013-03-27 OncoTherapy Science, Inc. Process for screening a drug response in cancer patients
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
EP1980629A3 (en) * 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers
WO2005032495A2 (en) * 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US20070110710A1 (en) * 2003-11-05 2007-05-17 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
WO2005075680A1 (ja) * 2004-02-09 2005-08-18 Fuso Pharmaceutical Industries, Ltd. 核酸検出方法およびその利用
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
BRPI0518734A2 (pt) 2004-11-30 2008-12-02 Veridex Llc prognàstico de cÂncer de pulmço
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
EP1863930A2 (en) 2005-04-01 2007-12-12 NCC Technology Ventures Pte Limited Materials and methods relating to breast cancer classification
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
JP5171812B2 (ja) * 2006-04-27 2013-03-27 ユニベルシテ ドゥ モントリオール 移植片対宿主病のリスクの評価および低減
KR20090017655A (ko) * 2006-06-02 2009-02-18 글락소스미스클라인 바이오로지칼즈 에스.에이. 환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법
WO2009034055A1 (en) * 2007-09-10 2009-03-19 Novartis Forschungsstiftung, Zweigniederlassung Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
WO2020235827A1 (ko) * 2019-05-17 2020-11-26 연세대학교 산학협력단 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트

Also Published As

Publication number Publication date
EA201290107A1 (ru) 2012-10-30
JP2013505008A (ja) 2013-02-14
AU2010297248A1 (en) 2012-04-12
CN102597269A (zh) 2012-07-18
MX2012003329A (es) 2012-04-20
US20110070268A1 (en) 2011-03-24
BR112012006088A2 (pt) 2020-08-11
IL218313A0 (en) 2012-04-30
CA2773666A1 (en) 2011-03-24
GB0917457D0 (en) 2009-11-18
WO2011033095A1 (en) 2011-03-24
EP2478116A1 (en) 2012-07-25
SG179129A1 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
CN109790583B (zh) 对肺腺癌亚型分型的方法
CN113490850B (zh) 用于治疗乳腺癌的诊断和治疗方法
CN109863251B (zh) 对肺鳞状细胞癌亚型分型的方法
KR20130055553A (ko) 환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법
US20050129717A1 (en) Novel uses
US20100247580A1 (en) Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
TW200817680A (en) Method
CA2344995A1 (en) Cancer associated antigens and uses therefor
US20110177079A1 (en) Cancer-testis antigens
US6440663B1 (en) Renal cancer associated antigens and uses therefor
CN1227611A (zh) Mage－b家族成员的分离的核酸分子及其用途
US6635255B1 (en) CASB414:antigen overexpressed in several tumors
JP2002507425A (ja) セリンプロテアーゼであるヒトｃａｓｂ１２ポリペプチド
US20100166783A1 (en) Method
JP2003516734A (ja) 癌関連抗原およびその使用
JP2002507417A (ja) Ｐａｐ−１関連化合物
JP2009195236A (ja) 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
HK40057217B (zh) 用於治疗乳腺癌的诊断和治疗方法
EP1144622A2 (en) Polynucleotides and their application in diagnostics
HK1020074A (en) Isolated nucleic acid molecules which are members of the mage-b family and uses thereof
HK1072187A (en) Use of casb616 polypeptides and polynucleotides for cancer treatment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120418

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid